Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?

por Byng, Danalyn, Retèl, Valesca P., Schaapveld, Michael, Wesseling, Jelle, van Harten, Wim H.
Publicado 2021

Scenario drafting to anticipate future developments in technology assessment

por Retèl, Valesca P, Joore, Manuela A, Linn, Sabine C, Rutgers, Emiel JT, van Harten, Wim H
Publicado 2012

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations

por Franzen, Nora, Ziegler, Andreas, Romagnoli, Giorgia, Retèl, Valesca P., Offerman, Theo J.S., van Harten, Wim H.
Publicado 2022

Association between genomic recurrence risk and well-being among breast cancer patients

por Retèl, Valesca P, Groothuis-Oudshoorn, Catharina GM, Aaronson, Neil K, Brewer, Noel T, Rutgers, Emiel JT, van Harten, Wim H
Publicado 2013

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients

por Miquel-Cases, Anna, Retèl, Valesca P., Lederer, Bianca, von Minckwitz, Gunter, Steuten, Lotte M. G., van Harten, Wim H.
Publicado 2016

Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes

por Lindenberg, Melanie A., Retèl, Valesca P., van der Poel, Henk G., Bandstra, Ferdau, Wijburg, Carl, van Harten, Wim H.
Publicado 2022

Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study

por Retèl, Valesca P, Bouchardy, Christine, Usel, Massimo, Neyroud-Caspar, Isabelle, Schmidlin, Franz, Wirth, Gregory, Iselin, Christophe, Miralbell, Raymond, Rapiti, Elisabetta
Publicado 2014

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis

por van Amerongen, Rosa A, Retèl, Valesca P, Coupé, Veerle MH, Nederlof, Petra M, Vogel, Maartje J, van Harten, Wim H
Publicado 2016

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

por Lindenberg, Melanie A., Retèl, Valesca P., van den Berg, Joost H., Geukes Foppen, Marnix H., Haanen, John B., van Harten, Wim H.
Publicado 2018

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

por Verbeek, Joost G. E., de Jong, Vincent M. T., Wijnja, Hanna M., Jager, Agnes, Linn, Sabine C., Retèl, Valesca P., van Harten, Wim H.
Publicado 2023

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy

por Retèl, Valesca P, van der Molen, Lisette, Hilgers, Frans JM, Rasch, Coen RN, L'Ortye, Annemiek AAMHJ, Steuten, Lotte MG, van Harten, Wim H
Publicado 2011

Whole genome sequencing in oncology: using scenario drafting to explore future developments

por van de Ven, Michiel, Simons, Martijn J. H. G., Koffijberg, Hendrik, Joore, Manuela A., IJzerman, Maarten J., Retèl, Valesca P., van Harten, Wim H.
Publicado 2021

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room

por Patel, Sejal, Lindenberg, Melanie, Rovers, Maroeska M., van Harten, Wim H., Ruers, Theo J.M., Poot, Lieke, Retel, Valesca P., Grutters, Janneke P.C.
Publicado 2020

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

por Retèl, Valesca P., Steuten, Lotte M. G., Geukes Foppen, Marnix H., Mewes, Janne C., Lindenberg, Melanie A., Haanen, John B. A. G., van Harten, Wim H.
Publicado 2018

Health state utility and health-related quality of life measures in patients with advanced ovarian cancer

por van Stein, Ruby M., Hendriks, Florine J., Retèl, Valesca P., de Kroon, Cor D., Lok, Christianne A.R., Sonke, Gabe S., de Ligt, Kelly M., van Driel, Willemien J.
Publicado 2023

GERiatric Screening in the treatment of elderly patients with Ovarian Carcinoma (GERSOC): study protocol for a pragmatic, cluster randomised controlled trial

por van Soolingen, Neeltje J., Smorenburg, Carolina H., Hamaker, Marije E., Groen, Wim G., Retèl, Valesca P., Lok, Christianne A. R., van de Poll-Franse, Lonneke V., Trum, Johannes W.
Publicado 2020

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms

por Verbeek, Joost G. E., Atema, Vera, Mewes, Janne C., van Leeuwen, Marieke, Oldenburg, Hester S. A., van Beurden, Marc, Hunter, Myra S., van Harten, Wim H., Aaronson, Neil K., Retèl, Valesca P.
Publicado 2019

Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?

por Beck, Ann-Jean C. C., Kieffer, Jacobien M., Retèl, Valesca P., van Overveld, Lydia F. J., Takes, Robert P., van den Brekel, Michiel W. M., van Harten, Wim H., Stuiver, Martijn M.
Publicado 2019

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists

por Byng, Danalyn, Retèl, Valesca P., Engelhardt, Ellen G., Groothuis-Oudshoorn, Catharina G. M., van Til, Janine A., Schmitz, Renée S. J. M., van Duijnhoven, Frederieke, Wesseling, Jelle, Bleiker, Eveline, van Harten, Wim H.
Publicado 2021

Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for p...

por Beck, Ann-Jean C. C., Passchier, Ellen, Retèl, Valesca P., Stuiver, Martijn M., van der Molen, Lisette, Klop, Willem M. C., Navran, Arash, van Harten, Wim H., van den Brekel, Michiel W. M.
Publicado 2019